“Symbios and our new Aphria topical treatments are exciting new additions to our medical portfolio in Canada, providing our patients with a broader selection of unique product formats to meet their needs and preferences,” said Jim Meiers, president of Tilray Canada, in the release.
“As we look ahead, we remain focused on building momentum across our three medical brands – Symbios, Aphria, and Tilray – while meeting the large and growing demand for new, high-quality cannabis products that promote health, wellness, and wellbeing,” he said.